NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma ...Middle East

NANJING, China, July 31, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human...

Hence then, the article about nmpa and fda approved the first in human clinical trial applications to evaluate lbl 034 an anti gprc5d cd3 bispecific antibody developed by leads biolabs in relapsed refractory multiple myeloma was published today ( Monday 31/07/2023 - 07:21 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma )

Also on site :

• No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl
• Natural gas line rupture stops traffic on 5 Freeway in Castaic
• SK Telecom Unveils A.X K1, Korea's First 500B-Scale Hyperscale AI Model